Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluvoxamine + metformin
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluvoxamine + metformin is a combination of two repurposed drugs that has been studied for COVID-19 treatment. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) used to treat obsessive-compulsive disorder and depression, while metformin is a medication for type 2 diabetes. This combination was investigated in clinical trials, particularly the COVID-OUT trial, as a potential treatment to prevent severe COVID-19 outcomes and Long COVID. The metformin dose used in trials was typically titrated over 6 days to 1500 mg per day for 14 days, while fluvoxamine was administered at 50 mg twice daily for 14 days.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)PEN2–ATP6AP1–v-ATPase (Presenilin enhancer 2–ATP6AP1–vacuolar-type H+-ATPase complex)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on fluvoxamine + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluvoxamine + metformin.